Prostate Cancer & BPHArchives
Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration
Prostate Cancer & BPH 5 min.
Prostate cancer (PC) is the most common cancer and the second leading cause of cancer death among men in the USA [1, 2–3]. While early-stage PC has a favorable prognosis, survival rates decline significantly when the disease becomes metastatic or castration-resistant [3]. Androgen deprivation therapy...
Rising metastatic prostate cancer rates but narrowing racial gap
Prostate Cancer & BPH 5 min.
Black men are twice as likely to die from prostate cancer (PCa) compared to White men [1]. Although rates of more aggressive PCa subtypes appear to be higher among Black men [2, 3], a growing body of literature highlights the significant role of access to care and socioeconomic factors as major contributors...
Embedding genetic testing in the metastatic prostate cancer pathway: understanding patient and physician perspectives
Prostate Cancer & BPH 1 min.
To understand how genetic (homologous recombination repair [HRR], including BReast CAncer [BRCA]) testing is being embedded in clinical practice and identify testing challenges given global approvals of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) for metastatic prostate cancer (mPCa)....
Correlations of biochemical and clinical outcomes with 10-year results after robotic stereotactic body radiotherapy for localized prostate cancer
Prostate Cancer & BPH 4 min.
Prostate cancer is the second most common malignancy, after lung cancer, among men aged ≥ 65 years in Korea, with an age-specific incidence rate of 375.4 per 100,000 in 2020 [1]. Despite an increasing trend in incidence, prostate cancer carries one of the highest cancer survival rates, with a 5-year...
